Latest HCV Stories
-SVR(12) rates of 96 percent were achieved in both SAPPHIRE-I (new to therapy) and SAPPHIRE-II (treatment-experienced with pegylated interferon and ribavirin) in adult patients with genotype 1 chronic
The European Association for the Study of the Liver (EASL) will this week be announcing new on-line recommendations on the management of hepatitis C (HCV) at the International Liver Congress™ (ILC).
NEW YORK, March 25, 2014 /PRNewswire/ -- At the New York Viral Hepatitis Summit presented by the National Black Leadership Commission
NORTH CHICAGO, Ill., March 24, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present new data from its phase III hepatitis C development program at the 2014 International Liver Congress(TM) (ILC) in
Additional drug-drug interaction data for faldaprevir combined with commonly prescribed HIV medications also presented at CROI 2014 INGELHEIM, Germany and RIDGEFIELD, Conn., March
- Study Designed to Demonstrate Human Proof-of-Concept Results by YE 2014 - LA JOLLA, Calif., March 5, 2014 /PRNewswire/ -- Regulus Therapeutics Inc.
-- SVR(12) rates of 99 percent with and without ribavirin were achieved in genotype 1b patients new to treatment BOSTON, March 3, 2014 /PRNewswire/ -- The first detailed results
- Ninety-nine percent SVR(12) rates with and without ribavirin in certain patient types NORTH CHICAGO, Ill., Jan.
Researchers from Taiwan reveal that antiviral therapy for hepatitis C virus (HCV) improves kidney and cardiovascular outcomes for patients with diabetes.
Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. It consists of a core of genetic material surrounded by an icosahedra protective shell of protein. The genome consists of a single open reading frame that is 9600 nucleotide bases long. HCV replication takes several steps. It primarily replicates in the hepatocytes of the liver. It can also reproduce in peripheral blood mononuclear cells. There is a wide variety of genotypes and...
- Large; stout; burly.